DE69529156D1 - Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit - Google Patents

Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit

Info

Publication number
DE69529156D1
DE69529156D1 DE69529156T DE69529156T DE69529156D1 DE 69529156 D1 DE69529156 D1 DE 69529156D1 DE 69529156 T DE69529156 T DE 69529156T DE 69529156 T DE69529156 T DE 69529156T DE 69529156 D1 DE69529156 D1 DE 69529156D1
Authority
DE
Germany
Prior art keywords
chinazoline
bodying
hydrogenated
derivatives
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69529156T
Other languages
English (en)
Other versions
DE69529156T2 (de
Inventor
Xinfu Pan
Fanglong Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wex Medical Ltd
Original Assignee
Nanning Maple Leaf Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Maple Leaf Pharmaceutical Co Ltd filed Critical Nanning Maple Leaf Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69529156D1 publication Critical patent/DE69529156D1/de
Publication of DE69529156T2 publication Critical patent/DE69529156T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69529156T 1994-03-17 1995-03-11 Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit Expired - Lifetime DE69529156T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN94110873 1994-03-17
PCT/CN1995/000016 WO1995024903A1 (fr) 1994-03-17 1995-03-11 Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes

Publications (2)

Publication Number Publication Date
DE69529156D1 true DE69529156D1 (de) 2003-01-23
DE69529156T2 DE69529156T2 (de) 2003-09-25

Family

ID=5034790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529156T Expired - Lifetime DE69529156T2 (de) 1994-03-17 1995-03-11 Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit

Country Status (7)

Country Link
US (1) US5846975A (de)
EP (1) EP0750909B1 (de)
JP (1) JPH09510221A (de)
AU (1) AU1888195A (de)
DE (1) DE69529156T2 (de)
RU (1) RU2168331C2 (de)
WO (1) WO1995024903A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
AU7389098A (en) 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CN1203857C (zh) 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
AU2007200073B2 (en) * 2000-09-18 2010-02-25 Wex Medical Limited A Method of Analgesia
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1236773C (zh) 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050282836A1 (en) * 2004-06-22 2005-12-22 Weiyang Lin Solid orally ingestible formulations of tetrodotoxin
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
EP1853268A1 (de) * 2005-02-11 2007-11-14 Wex Pharmaceuticals Inc. Verwendung von natriumkanalblockern und ihrer analoga zur behandlung von nikotin-abhängigkeit
EP1714655A1 (de) * 2005-04-22 2006-10-25 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
EP1690541A1 (de) * 2005-02-11 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Verwendung eines Natriumkanalblockers und deren Analoga zur Behandlung von Nikotinabhängigkeit
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
EP1844781A1 (de) 2006-02-22 2007-10-17 Wex Pharmaceuticals Inc. Verwendung von Natriumkanalblockern für die Behandlung von vorzeitigen Wehen
CA2647235C (en) 2006-03-27 2019-03-12 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
CN100438873C (zh) * 2006-06-26 2008-12-03 黄致强 将河鲀毒素作为镇痛药的耐受抑制剂在制备复方镇痛制剂中的应用
US8957207B2 (en) 2009-03-24 2015-02-17 Proteus S.A. Methods for producing phycotoxins
ES2351025B1 (es) 2009-06-12 2011-10-05 Consejo Superior De Investigaciones Cientificas (10 %) Sintesis de intermedios de la ttx.
PE20160011A1 (es) * 2013-03-15 2016-02-10 Childrens Medical Center Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
CN110256453A (zh) * 2019-07-09 2019-09-20 江苏华豚药业有限公司 一种河豚毒素酯化物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1370905A (en) * 1971-01-26 1974-10-16 Astra Pharma Prod Local anaesthetic composition
US3898339A (en) * 1973-08-14 1975-08-05 Astra Pharma Prod Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
JPS5594319A (en) * 1979-01-09 1980-07-17 Yoshio Otaka Drug for external use consisting of liver oil of swellfish
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
JPH03153627A (ja) * 1989-11-11 1991-07-01 ▲ゆ▼　耀庭 河豚毒素を有効成分とする薬剤及びその製造方法並びに河豚毒素の抽出方法

Also Published As

Publication number Publication date
AU1888195A (en) 1995-10-03
EP0750909A4 (de) 2000-07-26
DE69529156T2 (de) 2003-09-25
WO1995024903A1 (fr) 1995-09-21
EP0750909B1 (de) 2002-12-11
JPH09510221A (ja) 1997-10-14
RU2168331C2 (ru) 2001-06-10
EP0750909A1 (de) 1997-01-02
US5846975A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
DE69529156D1 (de) Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit
ATE197122T1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
DE69505657D1 (de) Fluorcarbonetherhybriden enthaltende physiologich akzeptabele emulsionen und verwendungsverfahren
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69807459D1 (de) VERFAHREN ZUR HERSTELLUNG VON HOCHAKTIVEN kATALYSATOREN UND IHRE VERWENDUNG
DE69626542D1 (de) Brenner und seine Verwendung zur Herstellung von Synthesegas
DE69733137D1 (de) Inhibitoren von picornavirus 3c protease und verfahren zur herstellung und verwendung
ATE186447T1 (de) Zusammensetzung und verwendung
DE69324511D1 (de) Mehrschichtig geformter Gegenstand und Verfahren zur dessen Herstellung
ATE456954T1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
DE69832282D1 (de) Polysilazan-amine und verfahren zur herstellung
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE59610741D1 (de) Verfahren zur Herstellung von Deckelmaterial sowie dessen Verwendung
DE69808266D1 (de) Herstellung und verwendung von alpha-ketoamid derivate und anordnunge
DE69534371D1 (de) Wachstumsfaktoren enthaldende therapeutische homöopathische verdünnungen und verwendung
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
ATE308365T1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung
DE69815866D1 (de) Verwendung von shogaolen und gingerolen zur herstellung von deodoranzien
DE69713040D1 (de) Verfahren zur Herstellung von Cyclopropylacetylen und dessen Derivaten
DE69717367D1 (de) Elektrobeschichteter Gegenstand und Zusammensetzung zur Elektrobeschichtung
DE59606616D1 (de) Dicarbonsäurederivate und ihre Verwendung zur Herstellung von Poly-o-hydroxyamiden oder Poly-o-mercaptoamiden
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
ATE246499T1 (de) Trimebutinhaltiges arzneimittel und verfahren
DE59502325D1 (de) Arzneimittelszusammensetzung aus S-Milchsäure und dessen Verwendung
DE69804920D1 (de) Verfahren zur Herstellung von Furopyridin-Derivaten und Zwischenprodukten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WEX PHARMACEUTICALS INC., VANCOUVER, BRITISH C, CA

8327 Change in the person/name/address of the patent owner

Owner name: WEX MEDICAL LTD., HONG KONG, CN